Ultimovacs ASA

DB:7UM Stock Report

Market Cap: €6.4m

Ultimovacs Valuation

Is 7UM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 7UM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 7UM's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 7UM's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 7UM?

Key metric: As 7UM is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 7UM. This is calculated by dividing 7UM's market cap by their current book value.
What is 7UM's PB Ratio?
PB Ratio0.4x
BookNOK 191.01m
Market CapNOK 74.32m

Price to Book Ratio vs Peers

How does 7UM's PB Ratio compare to its peers?

The above table shows the PB ratio for 7UM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average14.8x
CNW co.don
1xn/a€6.5m
MDG1 Medigene
1.2x-4.1%€22.6m
T5O bioXXmed
13.2xn/a€1.4m
VSC 4SC
44xn/a€48.2m
7UM Ultimovacs
0.4x25.5%€74.3m

Price-To-Book vs Peers: 7UM is good value based on its Price-To-Book Ratio (0.4x) compared to the peer average (19.5x).

Price to Book Ratio vs Industry

How does 7UM's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
7UM 0.4xIndustry Avg. 2.4xNo. of Companies3PB00.61.21.82.43+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 7UM is good value based on its Price-To-Book Ratio (0.4x) compared to the European Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is 7UM's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

7UM PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.4x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 7UM's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 7UM forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.18
€0.49
+176.1%
56.5%€0.77€0.21n/a2
Nov ’25€0.14
€0.49
+255.6%
56.5%€0.77€0.21n/a2
Oct ’25€0.14
€0.49
+252.0%
56.5%€0.77€0.21n/a2
Sep ’25€0.23
€0.49
+114.1%
56.5%€0.77€0.21n/a2
Aug ’25€0.69
€0.57
-17.9%
38.5%€0.79€0.35n/a2
Jul ’25€0.67
€0.57
-14.7%
38.5%€0.79€0.35n/a2
Jun ’25€0.73
€0.57
-22.0%
38.5%€0.79€0.35n/a2
May ’25€0.63
€0.57
-9.7%
38.5%€0.79€0.35n/a2
Apr ’25€0.64
€0.57
-11.7%
38.5%€0.79€0.35n/a2
Mar ’25€11.72
€15.65
+33.5%
12.7%€17.63€13.67n/a2
Feb ’25€11.98
€15.07
+25.8%
18.0%€17.78€12.36n/a2
Jan ’25€10.24
€15.07
+47.1%
18.0%€17.78€12.36n/a2
Dec ’24€8.96
€14.17
+58.1%
18.0%€16.72€11.62n/a2
Nov ’24€8.11
€14.20
+75.1%
22.3%€17.37€11.03€0.142
Oct ’24€8.51
€14.20
+66.9%
22.3%€17.37€11.03€0.142
Sep ’24€6.14
€14.20
+131.3%
22.3%€17.37€11.03€0.232
Aug ’24€6.63
€14.11
+112.9%
21.6%€17.16€11.07€0.692
Jul ’24€6.59
€14.11
+114.2%
21.6%€17.16€11.07€0.672
Jun ’24€9.97
€14.11
+41.6%
21.6%€17.16€11.07€0.732
May ’24€10.54
€15.05
+42.8%
20.8%€18.19€11.91€0.632
Apr ’24€10.08
€15.05
+49.3%
20.8%€18.19€11.91€0.642
Mar ’24€10.50
€15.05
+43.4%
20.8%€18.19€11.91€11.722
Feb ’24€10.98
€15.94
+45.2%
21.2%€19.32€12.56€11.982
Jan ’24€10.44
€15.94
+52.7%
21.2%€19.32€12.56€10.242
Dec ’23€9.93
€15.94
+60.5%
21.2%€19.32€12.56€8.962

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Regeneron Pharmaceuticals

US$79.4b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

RGO

US$707.40

7D

-0.9%

1Y

-3.6%

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.70

7D

1.3%

1Y

89.7%

Collegium Pharmaceutical

US$966.2m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.00

7D

3.6%

1Y

22.9%